A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients
Recruiting in Palo Alto (17 mi)
+10 other locations
AY
Overseen byAnthony Yu, MD
Age: 18+
Sex: Female
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Memorial Sloan Kettering Cancer Center
No Placebo Group
Trial Summary
What is the purpose of this trial?
The purpose of this study is to test whether patients with breast cancer who are being treated with non-anthracycline trastuzumab therapy can safely be monitored for heart related side effects less often than usual.
Research Team
AY
Anthony Yu, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Eligibility Criteria
Inclusion Criteria
Age >/= 18 years
Newly diagnosed histologically confirmed primary invasive breast carcinoma (Stage I-IV)
Pathologically confirmed HER2-positive breast cancer
See 3 more
Treatment Details
Interventions
- Left Ventricular Ejection Fraction (Diagnostic Test)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: HER2-Positive Breast CancerExperimental Treatment1 Intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Trials
1,998
Recruited
602,000+
Lisa M. DeAngelis
Memorial Sloan Kettering Cancer Center
Chief Medical Officer since 2021
MD from Columbia University
Selwyn M. Vickers
Memorial Sloan Kettering Cancer Center
Chief Executive Officer since 2022
MD from Johns Hopkins University